Cel Sci Corporation (CVM)

[GD]

I think now the simple logical reason for the event delay is
MK trial selected and enrolled a very good number of patients
who lived longer, it is not very hard to do since SOC has 5 year OS
37%, if MK produces a homerun OS advantage 23+%, it does not need
3 month to analyze the whole data, now I think the best MK may produce
10% to 12% OS advantage, hopefully with clear biomarkers point to
which subset group patients benefitting the most, so CVM may have
pricing power after approval, if it take 4 or more month for data,
I am afraid MK trial fails the primary endpoint.